Clinical Trials in Predementia Stages of Alzheimer Disease
Clinical Trials in Predementia Stages of Alzheimer Disease
复制标题
DOI：
10.1016/j.mcna.2013.01.002
复制
发表时间：
2013-05-01
影响因子：
5.9
通讯作者：
Cummings, Jeffrey L.
中科院分区：
文献类型：
--
作者：
Pillai, Jagan A.;Cummings, Jeffrey L.
有效治疗阿尔茨海默病（AD）痴呆症是一个迫切的需要。越来越多的共识是，在AD治疗最近受挫后，需要在临床痴呆发作前进行有效的疾病修饰治疗，并减缓轻度症状的进展。识别AD高危人群和临床前人群对于针对AD的一级和二级预防临床试验变得越来越重要。本文综述了新一代AD临床试验中针对高危和临床前AD人群的策略和挑战。设计，结果的措施，并成功地完成针对这一人群的临床试验的复杂性进行审查。
Effective treatments of Alzheimer disease (AD) dementia are an urgent necessity. There is a growing consensus that effective disease-modifying treatment before the onset of clinical dementia and slowing the progression of mild symptoms are needed after recent setbacks in AD therapeutics. The identification of at-risk and preclinical AD populations is becoming important for targeting primary and secondary prevention clinical trials in AD. This article reviews the strategies and challenges in targeting at-risk and preclinical AD populations for a new generation of AD clinical trials. Design, outcome measures, and complexities in successfully completing a clinical trial targeting this population are reviewed.